Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
Clinical trial NCT05751018 · RECRUITING
Trial details
- NCT number
- NCT05751018
- Sponsor
- Peking Union Medical College Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-08
- Primary completion
- 2026-12-31
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.